Core Viewpoint - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, with over 275 patents issued and pending [1][3]. Company Presentation - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 12:00 p.m. ET and will be available for one-on-one investor meetings throughout the event [2]. Company Overview - FibroBiologics is based in Houston and is developing a pipeline of treatments targeting chronic diseases, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3]. - The company represents a new generation of medical advancements in cell therapy and tissue regeneration [3].
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference